<DOC>
	<DOCNO>NCT01100502</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multicenter phase 3 trial evaluate efficacy safety brentuximab vedotin ( SGN-35 ) best supportive care ( BSC ) compare placebo BSC treatment residual Hodgkin lymphoma ( HL ) follow autologous stem cell transplant ( ASCT ) .</brief_summary>
	<brief_title>A Phase 3 Study Brentuximab Vedotin ( SGN-35 ) Patients High Risk Residual Hodgkin Lymphoma Following Stem Cell Transplant ( The AETHERA Trial )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients HL receive ASCT previous 3045 day Patients high risk residual HL post ASCT Histologicallyconfirmed HL ECOG 0 1 Adequate organ function Previous treatment brentuximab vedotin Previously receive allogeneic transplant Patients determine best clinical response progressive disease salvage treatment immediately prior ASCT History another primary malignancy remission least 3 year Post ASCT current therapy systemic antineoplastic investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antigens , CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Disease , Hodgkin</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Monomethylauristatin E</keyword>
</DOC>